Hikma’s Vascepa Generic Approved But Launch Still A Mystery
Follows Favorable US District Court Ruling In March
Executive Summary
Hikma has eyes on launching a generic of Amarin’s Vascepa in the US following FDA approval and a favorable patent ruling at the district level in March. However, with a swift appeal filed by the originator in the works, the Jordanian firm is yet to pull the trigger.
You may also be interested in...
‘Swift’ Vascepa Victory Puts Hikma And Reddy’s In Pole Position
Hikma and Dr Reddy’s Laboratories are weighing launches of their generics to Amarin’s Vascepa after the US Court of Appeals for the Federal Circuit upheld a favorable lower court ruling. The originator said it would take its appeal to the next level and continued to raise doubts over supply capacity.
Hikma’s First-Half Profits Leap By A Quarter
Hikma has seen its reported operating profit jump by a quarter in the first half of 2020, as a lift from its injectables business helped to drive up turnover by almost a tenth.
Amarin Makes Vascepa Generics Prediction And Questions Supply
Amarin – and the industry at large – was stunned in March this year when Hikma and Dr Reddy’s walked away from court with an invalidity ruling against six Vascepa patents in the US. The originator’s CEO gave an impassioned update on the current state of play, including the potential for generics to launch ahead of a Federal Circuit ruling later this year or early in 2021.